title: Endpoints for multimodal clinical trials in stage III non-small cell lung cancer (NSCLC): a consensus report.
authors.forename: M R
authors.initials: MR
authors.lastname: Green
authors.forename: J D
authors.initials: JD
authors.lastname: Cox
authors.forename: A
authors.initials: A
authors.lastname: Ardizzoni
authors.forename: R
authors.initials: R
authors.lastname: Arriagada
authors.forename: G
authors.initials: G
authors.lastname: Bureau
authors.forename: S
authors.initials: S
authors.lastname: Darwish
authors.forename: G
authors.initials: G
authors.lastname: Deneffe
authors.forename: M
authors.initials: M
authors.lastname: Fukuoka
authors.forename: D
authors.initials: D
authors.lastname: Joseph
authors.forename: R
authors.initials: R
authors.lastname: Komaki
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D009367:Neoplasm Staging